What is ANI Pharmaceuticals's remainder of fiscal year 2024?

ANI Pharmaceuticals (ANIP) reported remainder of fiscal year 2024 of $51.78M in Q1 2026.

How has ANI Pharmaceuticals's remainder of fiscal year 2024 changed year-over-year?

ANI Pharmaceuticals's remainder of fiscal year 2024 decreased by 14.1% year-over-year, from $60.31M to $51.78M.

ANI Pharmaceuticals ANIP Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

ViatrisVTRS

——

Aurinia PharmaceuticalsAUPH

——

AmgenAMGN

——

OrganonOGN

——

Mirum Pharmaceuticals, Inc.MIRM

——

Cardinal HealthCAH

——

Other financials

Income statement

See full

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

See full

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

See full

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

See full

Market cap$1.89B+18.3%

Enterprise value$1.88B+5.8%

P/E20.5×—

P/S2×-0.3×

Profitability

See full

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

See full

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's remainder of fiscal year 2024?: ANI Pharmaceuticals (ANIP) reported remainder of fiscal year 2024 of $51.78M in Q1 2026.
How has ANI Pharmaceuticals's remainder of fiscal year 2024 changed year-over-year?: ANI Pharmaceuticals's remainder of fiscal year 2024 decreased by 14.1% year-over-year, from $60.31M to $51.78M.